NanoViricides, Inc. (NYSE American: NNVC) announced it has received regulatory approval from ACOREP, the local regulatory agency in the Democratic Republic of Congo (DRC), to initiate a Phase II clinical trial of NV-387 Oral Gummies for the treatment of the current Bundibugyo ebolavirus outbreak and other Ebola viruses. The company has contracted Om Sai Clinical Research Private Limited as the contract research organization, with initial trial preparations already underway to accelerate first patient dosing.
According to the company, sufficient quantities of NV-387 Oral Gummies are already in the DRC to begin the trial. NV-387 is an investigational broad-spectrum antiviral designed to mimic host-side features required by viruses for infection. The oral formulation could offer significant advantages in resource-limited outbreak settings compared with treatments requiring intravenous infusion, which are often logistically challenging in remote areas.
The urgency of the trial is underscored by data from the World Health Organization, which reported 4,141 confirmed cases and 1,889 confirmed deaths from the current Bundibugyo ebolavirus outbreak in the DRC as of Aug. 6, 2026. The ongoing outbreak has highlighted the need for effective, easily deployable treatments. An oral therapy like NV-387 could potentially be administered more widely and quickly, improving patient outcomes and helping to contain the spread of the virus.
NanoViricides is a clinical-stage company focused on creating special purpose nanomaterials for antiviral therapy. Its lead drug candidate, NV-387, is being developed as a broad-spectrum antiviral for multiple indications, including respiratory infections, MPOX, and Ebola. The company holds a worldwide exclusive perpetual license to TheraCour nanomedicine technology for several viruses, including Ebola/Marburg viruses.
The approval marks a significant milestone for NanoViricides, moving its lead candidate into a Phase II trial for a high-priority viral threat. If successful, NV-387 could provide a much-needed oral treatment option for Ebola, potentially reducing mortality and easing the burden on healthcare systems during outbreaks.
For more information on the full press release, visit https://ibn.fm/2Pqu0.
